Personalis Inc (PSNL) Stock Price, Quote & News

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 752 1300

Fax: 650 752 1301

Website: www.personalis.com

Address:

6600 Dumbarton Circle, Fremont, United States

Universaal Dec. 6 at 12:50 AM

$PSNL huge volume ah maybe institutional buying? Some sort of price manipulation

0 · Reply

marcopol0 Dec. 5 at 6:52 PM

$PSNL Honestly don’t understand if the Foresight NTRA thing is good. The terms about single digit royalties is disappointing considering NTRA is going to be a big beneficiary of our tech. What do you all think?

1 · Reply

Universaal Dec. 5 at 6:25 PM

$VSTM next week biotech could tank $XBI $PSNL

1 · Reply

LucienW Dec. 5 at 6:15 PM

$PSNL and may I add - since they are already doing these tests and incurring all the costs and expenses, next year the majority of the reimbursed revenue will feed directly into the bottom line. Break even is not far from the horizon

1 · Reply

Wax_Bean_futures Dec. 5 at 6:09 PM

$PSNL added more. I keep telling myself no more, I'm over-extended on one stock, but here I am. Need over $30/share lol. Let's Go!

1 · Reply

LucienW Dec. 5 at 5:52 PM

$PSNL although I’m not a fan of the dilution, I am surprised how the SP is still stuck around this level. Personally I think this is an easy double by next spring when they release their FY26 guidance, which will have taken the reimbursed revenue into account - even assuming only 35k tests and no growth for the rest of the business, FY26 revenue would double YoY

1 · Reply

BioTechNoir Dec. 5 at 5:42 PM

$PSNL irrational, still

0 · Reply

degeneratetrader23 Dec. 5 at 5:00 PM

$PSNL bounced right off of the trendline ( 9.43) just like it did on 12/1.

0 · Reply

LucienW Dec. 5 at 4:34 PM

$PSNL added

0 · Reply

degeneratetrader23 Dec. 5 at 4:25 PM

$PSNL mr market does not like today's developments.

0 · Reply

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 25 days ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 4, 2025, 9:46 PM EST - 4 weeks ago

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 4 weeks ago

Personalis Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 6 weeks ago

Personalis to Announce Third Quarter 2025 Financial Results

Oct 16, 2025, 9:00 AM EDT - 7 weeks ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Sep 15, 2025, 5:35 PM EDT - 2 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:05 PM EDT - 3 months ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 3, 2025, 4:05 PM EDT - 3 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Aug 27, 2025, 4:01 PM EDT - 3 months ago

Personalis to Participate in Upcoming Investor Conferences

Aug 6, 2025, 8:11 AM EDT - 4 months ago

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

SMCI

Aug 6, 2025, 5:14 AM EDT - 4 months ago

Personalis (PSNL) Q2 Revenue Falls 24%

Aug 5, 2025, 10:49 PM EDT - 4 months ago

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:01 PM EDT - 4 months ago

Personalis Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 4 months ago

Personalis to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 4:00 PM EDT - 5 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Jun 3, 2025, 4:00 PM EDT - 6 months ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 2, 2025, 4:00 PM EDT - 6 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

May 22, 2025, 6:00 AM EDT - 7 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 14, 2025, 4:01 PM EDT - 7 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 6, 2025, 8:41 PM EDT - 7 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 7 months ago

Personalis Reports First Quarter 2025 Financial Results

Apr 28, 2025, 5:00 PM EDT - 7 months ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 22, 2025, 4:01 PM EDT - 8 months ago

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 6:00 AM EDT - 8 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Mar 26, 2025, 4:01 PM EDT - 9 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 6:00 AM EST - 9 months ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Feb 27, 2025, 7:40 PM EST - 10 months ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 10 months ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 4:21 PM EST - 10 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Feb 18, 2025, 4:01 PM EST - 10 months ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 14, 2025, 10:50 AM EST - 10 months ago

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 13, 2025, 4:01 PM EST - 10 months ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 4:01 PM EST - 11 months ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 5:00 AM EST - 11 months ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 7, 2025, 4:01 PM EST - 11 months ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 9:00 AM EST - 1 year ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 16, 2024, 8:00 AM EST - 1 year ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Nov 20, 2024, 4:01 PM EST - 1 year ago

Personalis to Participate at Upcoming Investor Conferences

Nov 6, 2024, 8:11 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 1 year ago

Personalis Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:01 PM EST - 1 year ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Oct 23, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Third Quarter 2024 Financial Results

Sep 16, 2024, 9:00 AM EDT - 1 year ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Aug 18, 2024, 7:47 AM EDT - 1 year ago

Personalis: Resetting My Strategy Following The Q2 Beat

Aug 16, 2024, 8:30 AM EDT - 1 year ago

Personalis and Tempus Announce Expanded Collaboration

TEM

Aug 7, 2024, 11:09 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Jul 24, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2024 Financial Results

Universaal Dec. 6 at 12:50 AM

$PSNL huge volume ah maybe institutional buying? Some sort of price manipulation

0 · Reply

marcopol0 Dec. 5 at 6:52 PM

1 · Reply

Universaal Dec. 5 at 6:25 PM

$VSTM next week biotech could tank $XBI $PSNL

1 · Reply

LucienW Dec. 5 at 6:15 PM

1 · Reply

Wax_Bean_futures Dec. 5 at 6:09 PM

$PSNL added more. I keep telling myself no more, I'm over-extended on one stock, but here I am. Need over $30/share lol. Let's Go!

1 · Reply

LucienW Dec. 5 at 5:52 PM

1 · Reply

BioTechNoir Dec. 5 at 5:42 PM

$PSNL irrational, still

0 · Reply

degeneratetrader23 Dec. 5 at 5:00 PM

$PSNL bounced right off of the trendline ( 9.43) just like it did on 12/1.

0 · Reply

LucienW Dec. 5 at 4:34 PM

$PSNL added

0 · Reply

degeneratetrader23 Dec. 5 at 4:25 PM

$PSNL mr market does not like today's developments.

0 · Reply

arribaStocktrading Dec. 5 at 4:10 PM

$PSNL current ST support @ 9.70. If Personalis is Thor, then Natera must surely be Loki.

0 · Reply

kilo1968 Dec. 5 at 3:57 PM

$PSNL 4.2 Change of Control Fee. If Foresight undergoes a Change of Control and the Acquirer of Foresight is a Specified Acquirer, Foresight shall (a) pay Personalis a one-time payment of [***] U.S. Dollars ($[***]) (the “Change of Control Fee”) within [***] days of the closing of the associated Change of Control of Foresight, and (b) the royalty rate for that portion of annual Net Sales of Royalty Products and Services in a given Calendar Year exceeding $[***] shall be increased from [***]% to [***]% for the remainder of all Royalty Terms, commencing from the first Calendar Quarter following the closing date of such Change of Control.

1 · Reply

LukasWo Dec. 5 at 2:48 PM

$PSNL Natera bought foresight, probably indicating they cannot develop the tech in-house. If Natera can't, who else can? And Foresight pays royalty to Personalis. Think about it

1 · Reply

LordBrypto Dec. 5 at 1:40 PM

$PSNL $20

1 · Reply

moneyMunkey Dec. 5 at 1:03 PM

$PSNL Natera is buying foresight Dx … who has a IP agreement with Personalis. seems to validate Personalis technology.

0 · Reply

Wax_Bean_futures Dec. 4 at 9:23 PM

$PSNL nice close 👍

0 · Reply

MoneyGroupLLC Dec. 4 at 7:40 PM

Enter: $PSNL Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $0.82 - $0.90 Sell Price: $1.81 Profit : +121% (Turn every $1 into $2.21) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Wax_Bean_futures Dec. 4 at 6:59 PM

$PSNL

2 · Reply

HedgeAlerts Dec. 4 at 7:11 AM

Hedge Alert Live - Protect Your Portfolio Contract: $PSNL $10.00 Put · DEC 19, 2025 Exp Entry Price: $0.88 - $2.00 Exit Price Target: $1.75 Profit Margin: +99% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

TripleWitch Dec. 3 at 9:11 PM

$PSNL there’s that 🏧

0 · Reply

SuperGreenToday Dec. 3 at 7:11 PM

$PSNL Share Price: $10.35 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $2.55 – $3.15 Target Zone: $4.51 – $5.51 Potential Upside: 67% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

GGator Dec. 3 at 6:22 PM

$PSNL ok I’m not going to say goodbye to single digits another time. Hopefully this is it!

1 · Reply

Market Cap	896.92M
Revenue (ttm)	84.61M
Net Income (ttm)	-81.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-96.06%
Debt to Equity Ratio	0.00

Volume	1,439,300
Avg Vol	1,439,208
Day's Range	N/A - N/A
Shares Out	88.80M
Stochastic %K	71%
Beta	1.99
Analysts	Strong Sell
Price Target	$10.71